Mass Tort

Invokamet® / Invokana® Diabetes Medication

Type 2 Diabetes Medications – Defective Drug Attorney – Burg Simpson

Invokana ® (canagliflozin) is a prescription diabetes medication that is used in combination with diet and exercise to lower blood sugar levels and lower blood glucose levels in adults with type 2 diabetes.

The most serious Invokamet ® and Invokana ® side effects are kidney damage, ketoacidosis, and myocardial infarction:

  • Kidney Failure (also known as renal failure diagnosis) occurs when the kidneys stop functioning correctly and do not properly filter waste products from the blood. Kidney failure is a serious medical conditions that requires treatment. These kidney problems can cause fatigue, confusion, weakness, muscle damage, and death.
  • Diabetic Ketoacidosis occurs when the body cannot use glucose for energy and instead breaks down fat and proteins. As a result, dangerous levels of acid, known as ketones, build up in the body causing symptoms such as nausea, vomiting, abdominal pain, and shortness of breath.  This is a serious, life-changing medical condition that requires intensive treatment and can result in organ failure, coma, or even death.
  • Myocardial Infarction (also known as a heart attack) occurs when blood flow is restricted to your heart, depriving it of oxygenated blood, causing heart failure. When the heart has a lack of oxygen supply for too long, the tissues begin to die. A heart attack is a serious medical condition that can cause death and requires immediate medical attention.

The claim in the Invokana® cases is that if the manufacturer had warned of the possible risks involved with taking this medicine, patients could have possibly avoided these serious complications. Patients taking Invokana® would have also been warned from the beginning to keep a close eye on potential health issues. Burg Simpson is an award-winning law firm that has your best interests at heart. Contact one of our best product liability lawyers today by filling out the Free Case Evaluation form if you have been harmed by this drug.

Additional Information

In clinical trials, patients on Invokana ® were more likely to develop diabetic ketoacidosis than patients on other SGLT2 inhibitors. Ketoacidosis normally involves very high level of sugar in the blood. Many Invokana ® users with normal or mildly-elevated blood-sugar have developed ketoacidosis. Because of ketoacidosis’ unusual symptoms, diagnosis can be delayed, resulting in a delay in treatment until it becomes life-threatening.

On May 15, 2015, the FDA issued a Safety Announcement that linked Invokana ® and other sodium-glucose cotransporter-2 (SGLT2) inhibitors to ketoacidosis. Additionally, on December 4, 2015, the FDA required Janssen to update Invokana®’s label to include ketoacidosis. The FDA received more than 70 reports of patients who were hospitalized with ketoacidosis between March 2013 and May 2015. It is not known how many cases were not reported to the FDA.

On February 25, 2016, the European Medicines Agency recommended a warning to doctors and patients in order to minimize the risk of diabetic ketoacidosis symptoms in patients taking SGLT2 inhibitors. If you have been affected by the serious effects of Invokana ®, call a Burg Simpson Dangerous Drug Attorney now to discuss the details of your case by filling out the Free Case Evaluation form.

Diabetic ketoacidosis is a medical condition that occurs when toxic wastes known as ketones build up in the bloodstream. The condition usually occurs when the body does not have enough insulin to use glucose (sugar) as a source of energy. Instead of using glucose as an energy source, the body starts burning fat cells, which releases ketones into the bloodstream. High levels of ketones in the body can result in the person going into a diabetic coma (passing out for a long time) or even death.

Symptoms of Diabetic Ketoacidosis can include:

  • Nausea and vomiting
  • Stomach pain
  • Tiredness, fatigue or decreased alertness
  • Deep, rapid breathing
  • Dry skin and mouth
  • Flushed face
  • Frequent urination or thirst that lasts a day or more
  • Fruity-smelling breath
  • Headache
  • Muscle stiffness or aches

Call Burg Simpsons attorney office for experienced legal assistance with your case today!

On June 14, 2016, the FDA issued a Drug Safety Communication about the association between Invokana ® and acute kidney problems. The Safety Communication reported that “From March 2013, when canagliflozin was approved, to October 2015, FDA received reports of 101 confirmable cases of acute kidney injury, some requiring hospitalization and dialysis, with canagliflozin or dapagliflozin use. This number includes only reports submitted to FDA, so there are likely additional cases about which we are unaware.

In approximately half of the cases, the events of acute kidney failure occurred within 1 month of starting the drug, and most patients improved after stopping it. Some cases occurred in patients who were younger than 65 years. Some patients were dehydrated, had low blood pressure, or were taking other medicines that can affect the kidneys. The FDA required Janssen to change Invokana®’s label to warn about the risk of acute kidney injury.

Independent medical researchers have also identified Invokana®’s association with kidney problems. According to QuarterWatch, a nonprofit group monitoring serious adverse event reports, Invokana®’s first year of sales was accompanied by numerous “serious injuries involving kidney function.”

In clinical trials, 13 patients on Invokana ® suffered an adverse cardiovascular event such as a heart attack or stroke during the first 30 days of treatment, compared to just one patient on a placebo. Data from the CANVAS trial (Canagliflozin Cardiovascular Assessment Study) linked Invokana ® to a 46% increased risk of cardiovascular events in the first 30 days of use. However, the product information related to Invokana ® does not adequately warn of this increase in risk.

You may be entitled to compensation if you or your loved one used Invokana ® or Invokamet ® as medical treatment for diabetes and developed kidney damage, ketoacidosis, or a myocardial infarction. Call us today to speak with a knowledgeable Burg Simpson Mass Tort Lawyer about the potential for your case.

No. We offer our clients a free, no-obligation case assessment by filling out the Free Case Evaluation form found on this page. We pay for the cost of obtaining your medical records, any expert reviews, and court filing fees. We only receive reimbursement and a fee for our work if the defendant manufacturer pays your claim. If you do not receive a recovery, then you owe Burg Simpson nothing.

Act now and don’t wait! Many have already filed a claim for Invokana ® lawsuits. Indecision could mean losing the opportunity to receive just compensation. The time you have to file a claim depends on a variety of different factors, including the state in which you live. Please call us now to discuss what those factors are.

This latest diabetes treatment was developed by Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) and approved by the FDA in March 2013. It was the first drug in a new class known as sodium-glucose cotransporter-2 (“SGLT2”) inhibitors.  Invokana ® helps improve glycemic control by causing the kidneys to remove sugar through the urine.  In August 2014, Janssen received FDA approval to begin to market Invokamet ® in the United States. Invokamet ® a fixed-dose therapy combining Invokana ® and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes.

If you or a loved one has suffered the serious illnesses that Invokana® can cause, fill out the Free Case Evaluation form as soon as you can to discuss your case with a Burg Simpson Drug Attorney

Invokana ® Case Timeline To Date:

  • March 2013: Invokana® approved by the FDA.
  • August 2014: Invokamet® approved by the FDA.
  • May 15, 2015: FDA issued a safety announcement linking Invokana® to ketoacidosis.
  • December 4, 2015: FDA required Janssen to update Invokana®’s label to warn doctors and patients of the risk of ketoacidosis.
  • February 25, 2016: European Medicines Agency also recommended a warning to doctors and patients in order to minimize the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors.
  • June 14, 2016: FDA issued a Drug Safety Communication about the association between Invokana ® and acute kidney injury.
  • December 7, 2016: Judicial Panel on Multidistrict Litigation transfers all Invokana® and Invokamet® cases filed in federal courts around the United States to the Honorable Brian R. Martinotti, District Judge for the U.S. District Court of New Jersey.
The Trial Lawyer Magazine honors Michael Burg; firm of Burg Simpson Eldredge Hersh & Jardine

 February 6, 2017

The Trial Lawyer Magazine honors Michael Burg; firm of Burg Simpson Eldredge Hersh & Jardine

Michael S. Burg Named One of America’s 50 Most Influential Trial Lawyers Burg Simpson Eldredge Hersh & Jardine Named One of America’s 25 Most Influential Law Firms The Trial Lawyer magazine honorees to be celebrated at The National Trial Lawyers’ annual summit Denver, CO – Burg Simpson Eldredge Hersh & Jardine, PC is proud to… Read more »

7 Burg Simpson Shareholders Named to 2017 Top Lawyers List

 January 23, 2017

7 Burg Simpson Shareholders Named to 2017 Top Lawyers List

Denver, Colorado – Burg Simpson Eldredge Hersh & Jardine, P.C. is pleased to announce that seven shareholders have recently been named to 5280 Magazine’s 2017 Top Lawyers list. Founded in 1993, 5280 is the largest local magazine in Colorado. The Burg Simpson attorneys selected for inclusion in 5280 Top Lawyers are: Michael S. Burg –… Read more »

2016: Another Year Burg Simpson Changed Lives

 December 8, 2016

2016: Another Year Burg Simpson Changed Lives

The Burg Simpson attorneys had another outstanding year changing the lives of those they represent. The firm’s ability to properly value cases—whether personal injury, medical malpractice, construction defect, or mass tort—and fight tirelessly as a cohesive team to obtain the compensation its clients deserve sets Burg Simpson apart. Here is just a small sample of… Read more »

Janet Abaray Profiled in Super Lawyers Magazine

 December 7, 2016

Janet Abaray Profiled in Super Lawyers Magazine

The most recent edition of Super Lawyers Magazine features a profile on Burg Simpson Ohio’s managing shareholder, Janet Abaray. In the feature, Ms. Abaray discusses some of the highlights of her career, the art of “looking around corners” in a case, taking on big pharma, and a well-known class action against the Bengals. Amongst her… Read more »

Recall Alert: Comprehensive Reverse Shoulder Recalled by Zimmer Biomet

 February 17, 2017

Recall Alert: Comprehensive Reverse Shoulder Recalled by Zimmer Biomet

Zimmer Biomet has issued a Class I Recall of its Comprehensive Reverse Shoulder due to higher than reported fracture rates.  Zimmer Biomet issued the recall on December 15, 2016.  The Zimmer recall includes thousands of Comprehensive Reverse Shoulders.  The recalled devices were distributed between October 2008 and September 2015.  As part of the shoulder recall,… Read more »

Mike Burg Holds First Book Signing for Trial by Fire at Tattered Cover

 August 18, 2016

Mike Burg Holds First Book Signing for Trial by Fire at Tattered Cover

Last month at the Tattered Cover Book Store in Denver, Colorado, a crowd of over 100 were treated to an evening with Burg Simpson attorney and author, Mike Burg. Speaking about his new book, Trial By Fire: One Man’s Battle to End Corporate Greed and Save Lives, Mike discussed his childhood and his motivations that… Read more »

Talcum Powder and Ovarian Cancer?

 August 12, 2016

Talcum Powder and Ovarian Cancer?

Many cases of ovarian cancer diagnosed each year may have been caused by the regular use of talcum powder. Talc is a mineral made up of silicon, magnesium and oxygen. Because of its unique ability to absorb moisture, talc is common ingredient in Johnson & Johnson Baby Powder, Shower to Shower, and other household products… Read more »

Contaminated Olympus Endoscope Lead to Outbreak of Fatal Bacterial Infections

 July 28, 2016

Contaminated Olympus Endoscope Lead to Outbreak of Fatal Bacterial Infections

Olympus’ Surgical Scope Exposes Patients to Risk of Infection Medical device manufacturer Olympus Medical Systems Corp. (Olympus) is under investigation because its surgical device has been linked to serious infections, including some strains of drug-resistant bacteria known as “superbugs.” Olympus manufactures and sells a device called a duodenoscope that is used in endoscopic retrograde cholangiopancreatography… Read more »

Ring of Fire: Even Republicans Are Disgusted by The Republican Party

 May 3, 2016

Ring of Fire: Even Republicans Are Disgusted by The Republican Party

A Ring of Fire first! Host Farron Cousins talks to former Senator Alan Simpson in a unique opportunity on Ring of Fire to speak with a Republican about the current state of the Republican Party.

CBS 4: Michael Burg Inducted to Trial Lawyer Hall of Fame

 April 28, 2016

CBS 4: Michael Burg Inducted to Trial Lawyer Hall of Fame

CBS 4 in Denver highlights Burg Simpson attorney Michael S. Burg’s induction into the Trial Lawyer Hall of Fame

Radio 850KOA: Michael Burg Inducted to Trial Lawyer Hall of Fame

 April 28, 2016

Radio 850KOA: Michael Burg Inducted to Trial Lawyer Hall of Fame

Denver’s Radio 850KOA ran a news story about Michael Burg’s induction into the Trial Lawyer Hall of Fame.

Burg Simpson Legal Minute: Civil Justice System

 April 21, 2016

Burg Simpson Legal Minute: Civil Justice System

Burg Simpson shareholder Calvin Tregre Jr. examines changes to the civil justice system, where limitations have been placed on monetary awards to seriously injured victims of corporate negligence. Are you protected?

Trial Talk magazine

 November 18, 2015

Trial Talk: Cross Appeal? Now What?

Burg Simpson Attorney and Shareholder Diane Vaksdal Smith’s article, published in CTLA’s Trial Talk, April/May 2015, addresses specifics of appellate practice and procedure. Download full article PDF

Net Neutrality

 November 18, 2015

Net Neutrality: A Panel Discussion

Rick D. Bailey contributes his opinion on Net Neutrality in this panel article published in Best Lawyers® Business Edition, Summer, 2015. Download full article PDF

The Trial Lawyer Magazine

 November 18, 2015

Homebuilders v. Homeowners

Threats to Shift an Already Tilted Playing Field More in Favor of Homebuilders Burg Simpson attorneys Jennifer A. Seidman and Ronald M. Sandgrund examine what could happen if lawmakers allow builders to take advantage of and mischaracterize the causes of the Great Recession’s lingering effects, and the facts regarding the real causes of the decline… Read more »

Rick Bailey - Hearing and Mishearing

 November 18, 2015

Hearing and Mishearing: Psychoanalytic Observations on the Attorney-Client Relationship

Trial lawyer Rick D. Bailey co-authored this white paper with David Stevens, a practicing psychoanalyst/clinical psychologist and associate professor at the university of Colorado Health Sciences Center. They address the attorney-client relationship throught the lens of psychoanalysis and cognitive neuroscience. Download full article PDF

Top 100 National Trial Lawyers Legal 500 Best Lawyers in America Super Lawyers US News 2014 US News 2014 Plantiffs Top 25 Most Influential Lawyers